AMD to Host Annual Meeting of Stockholders

AMD (NASDAQ: AMD) will hold its Annual Meeting of Stockholders on Wednesday, May 14, 2025 at 9 a.m. PDT as a virtual meeting accessible at https:www.virtualshareholdermeeting.comAMD2025 . Forward-looking and other material information may be discussed during the meeting.

The matters to be voted on at the meeting are in AMD's 2025 Proxy Statement filed with the U.S. Securities and Exchange Commission. The Proxy Statement and AMD's Annual Report on Form 10-K can be accessed at ir.amd.com .

The real-time audio webcast of the meeting will be available at https://www.virtualshareholdermeeting.com/AMD2025 . A replay of the audio webcast can be accessed at ir.amd.com approximately 24 hours after the conclusion of the live event and will be available for up to one year after the meeting.

About AMD
For more than 55 years AMD has driven innovation in high-performance computing, graphics and visualization technologies. Billions of people, leading Fortune 500 businesses and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ: AMD) website , blog , LinkedIn , Facebook and X pages.

AMD, the AMD Arrow logo and the combination thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.

Contact
Phil Hughes
AMD Communications
512-865-9697
phil.hughes@amd.com

Liz Stine
AMD Investor Relations
(720) 652-3965
liz.stine@amd.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AMD
The Conversation (0)
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its first quarter of... Keep Reading...
Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors,... Keep Reading...
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth... Keep Reading...
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the second quarter of the fiscal year 2025... Keep Reading...

Interactive Chart

Latest Press Releases

Related News